MorphoSys and Galapagos Expand Antibody Alliance
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
MorphoSys AG and Galapagos NV have announce that they have expanded their antibody alliance in bone and joint diseases. Based on the solid progress made so far, the partners have agreed to add another antibody target to the alliance, thereby increasing the total number of programs to four.
The alliance aims to discover and develop antibody therapeutics based on novel modes of action in bone and joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis. As part of the initial agreement, three targets were selected for the collaboration. Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific in vitro and in vivo experiments.
In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development. Based on this, Galapagos and MorphoSys have now added a fourth antibody target to the alliance.
The partners have prioritized the targets in order to maximize the value and IP position of the respective therapeutic antibody programs.
"This collaboration provides Galapagos with a platform to develop antibody drugs for our proprietary targets," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "This, together with more than 40 R&D small molecule programs, solidifies our leading position in discovering innovative approaches to address diseases with unmet medical need."
The alliance aims to discover and develop antibody therapeutics based on novel modes of action in bone and joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis. As part of the initial agreement, three targets were selected for the collaboration. Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific in vitro and in vivo experiments.
In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development. Based on this, Galapagos and MorphoSys have now added a fourth antibody target to the alliance.
The partners have prioritized the targets in order to maximize the value and IP position of the respective therapeutic antibody programs.
"This collaboration provides Galapagos with a platform to develop antibody drugs for our proprietary targets," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "This, together with more than 40 R&D small molecule programs, solidifies our leading position in discovering innovative approaches to address diseases with unmet medical need."
